A Phase 4 interventional study of Ganirelix Acetate and Cetrorelix Acetate in Infertility/Sterility, sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-27.
Sponsored by Università degli Studi 'G. d'Annunzio' Chieti e Pescara · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing cetrorelix in Infertility — 1 open to participants now, 1 under way, none of them phase 3. cetrorelix · Infertility.
Among the 17 studies testing cetrorelix in Infertility, this one is the 8th largest by planned enrollment, is one of 2 that started in 2017, is one of 10 in phase 4, and was the 11th registered.
2,090 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →1 of the 17 studies testing cetrorelix in Infertility is open now, in 1 country. Recruiting first, the newest first:
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Sites in China
Ages 20–42 · Women only · Healthy volunteers
By country, each count listing its studies:
cetrorelix: first FDA approval 2000 (CETROTIDE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 39 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
This study's planned enrollment of 100 is below the median of 134 across 1,415 interventional studies indexed under Infertility.
Median enrollment 99 across the 17 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 10 most frequent:
Università degli Studi 'G. d'Annunzio' Chieti e Pescara is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Università degli Studi 'G. d'Annunzio' Chieti e Pescara has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing cetrorelix in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Recombinant gonadotropins are currently used for ovarian stimulation in women undergoing to IVF for infertility. Recently new flexible protocols have been introduced: the "single dose" and "multiple dose" protocol. The single dose protocol is performed just using Cetrorelix by the administration of a single injection of Cetrorelix 3 mg subcutaneous when the lead follicle is ≥ 14 mm. The multiple dose protocol consider the daily administration of Cetrorelix 0.25 mg subcutaneous or Ganirelix 0.25 mg subcutaneous when the lead follicle is ≥ 14 mm and until the realization of hCG criteriaThere are few data from letterature about the comparison of the efficacy in pitituary suppression and pregnancy outcome of Ganirelix and Cetrorelix.
Objective: to compare the efficacy in pituitary gonadotropin suppression and IVF outcome of multiple dose flexible gonadotrophin-releasing hormone (GnRH) antagonist administration according to follicular size using daily injection of Cetrorelix or Ganirelix.
Interventions : patients are randomly assigned in to Cetrorelix acetate group or Ganirelix acetate group. Multiple dose of Cetrorelix acetate (0.25 mg) or multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met.Oocyte maturation trigger is performed by the administration of subcutaneous r-hCG (250 μg) or of intramuscular hCG (10,000 IU). After 36 hour transvaginal oocyte retrieval is performed followed by ICSI and embrio transfer (72 hours later).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Drug: Ganirelix Acetate
multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
Drug: Cetrorelix Acetate
multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
serum LH levels
percentage of patients not having serum levels of LH ≥ 10IU\\L (defined as premature LH surge) on the day of hCG administration.
Time frame: through study completion,an average of 9 months
number of follicles ≥ 14mm on the day of hCG administration
number of follicles ≥ 14mm
Time frame: through study completion,an average of 9 months
FSH serum levels on the day of hCG administration
mUI/ml
Time frame: through study completion,an average of 9 months
FSH on the day of antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
FSH serum level on the day after the antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
LH serum level on the day of antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
LH serum level on the day after the antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
E2 serum level on the day of antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
E2 serum level on the day after the antagonist administration
mUI/ml
Time frame: through study completion,an average of 9 months
number of oocyte retrieved
how many oocyte were retrieved on transvaginal oocyte retrieval
Time frame: through study completion,an average of 9 months
number of metaphase II oocyte retrieved
how many metaphase II oocyte were retrieved on transvaginal oocyte retrieval
Time frame: through study completion,an average of 9 months
embryos obtained for patients
how many embryos were obtained for patient for each arm
Time frame: 72 hours after transvaginal oocyte retrieval
grade A embryos transferred
number of grade A embryo were transferred for patient
Time frame: 72 hours after transvaginal oocyte retrieval
total dose of gonadotropins administered
number of Units of gonadotropin administered for Controlled Ovarian Hyperstimulation
Time frame: through study completion,an average of 9 months
duration of gonadotropin treatment
how many days were necessary to complete the Controlled Ovarian Hyperstimulation
Time frame: through study completion,an average of 9 months
percentage of patients developing OHSS
how many patient for each arm develop OHSS (Ovarian Hyperstimulation Syndrome)
Time frame: 15 days after the transvaginal oocyte retrieval
implantation rate
The number of gestational sacs observed divided by the number of embryos transferred.
Time frame: 30 days after the embyo transfer
pregnancy rate
The number of clinical pregnancy (Positive hCG test) divided by the number of embryos transferred
Time frame: 14 days after the transvaginal oocyte retrieval
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2017 (actual). Primary completion is estimated for Dec 2018, 13 months after the start.
Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 13 months is below that.
Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ganirelix · Cetrorelix
Università degli Studi 'G. d'Annunzio' Chieti e Pescara